About this episode

The episode discusses recent biotech IPOs, FDA policies, and updates on obesity treatments and rare diseases.

On this week’s episode, Graig Suvannavejh, Chris Garabedian, Eric Schmidt, and Yaron Werber kick off with a look at a big week for biotech IPOs, led by Veradermics and Eikon Therapeutics. The co-hosts note that this could mark the start of a healthy year for high‑quality IPOs, with many companies entering the market with mature assets Generate Biomedicines’ S‑1 filing was highlighted as another positive signal for the industry. The conversation moves to policy, including Amgen’s decision not to withdraw Tavneos after the FDA flagged data from a 2021 trial conducted by ChemoCentryx before it was acquired by Amgen. The group also discusses the narrowly passed spending bill that reauthorizes the FDA’s rare pediatric disease priority review voucher program and the White House’s rejection of fast‑track review for Compass Pathways’ psychedelic. In obesity news, the group discusses Dr. Makary’s signaling FDA will take action against compound pharmacies following HIMS’ announcement that they will provide compounded semaglutide pills. The co-hosts also highlight promising clinical data from Pfizer and Metsera’s GLP‑1 program and Amgen’s investigational MariTide, which seem to reaffirm…

More episodes of Biotech Hangout

• Episode 180 - April 17, 2026 · April 17, 2026 · 54 min
• Episode 179 - April 10, 2026 · April 10, 2026 · 60 min
• Episode 178 - April 3, 2026 · April 3, 2026 · 1h 1m
• Episode 177 - March 27, 2026 · March 27, 2026 · 56 min
• Episode 176 - March 13, 2026 · March 13, 2026 · 1h 1m
• Episode 175 - March 6, 2026 · March 6, 2026 · 52 min

Explore listener stats, chart rankings, contacts and more on the Biotech Hangout podcast page.